Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
2(29%)
Results Posted
25%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
3
43%
Ph phase_3
2
29%

Phase Distribution

2

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 23 (42.9%)
Phase 32 (28.6%)

Trials by Status

terminated114%
completed457%
active_not_recruiting229%

Recent Activity

2 active trials
Showing 5 of 7
active_not_recruitingphase_3

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05600777
active_not_recruitingphase_3

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05599191
completedphase_1

Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

NCT06179537
completedphase_2

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

NCT04693195
completedphase_2

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT04678206
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05600777Phase 3

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Active Not Recruiting
NCT05599191Phase 3

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Active Not Recruiting
NCT06179537Phase 1

Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

Completed
NCT04693195Phase 2

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

Completed
NCT04678206Phase 2

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Completed
NCT03979638Phase 2

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

Terminated
NCT03638180Phase 1

BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7